The study population consisted of 34 patients. The median number of examined lymph nodes (ELN) was 21 (range 15-28); the median number of positive lymph nodes (PLN) was 0 (range 0-8). Mean operative time was 240 min (sd 43.56, range 180-360 min), and conversion to open rate was 0%. Anastomotic leak rate was 0%. The median follow-up period was 28 months CONCLUSION: This pilot series represents a significant step forward in the development of completely vessel-sparing sigmoidectomy for adenocarcinoma. The study demonstrates the safety and feasibility of this innovative approach, which aims to achieve oncological radicality while preserving vital vascular structures. Notably, the postoperative outcomes observed in this study were comparable to those reported in the existing literature for the current standard of care at high-volume centers. Nevertheless, further validation through prospective and controlled investigations is essential before this technique can be fully incorporated into clinical practice.
Keyphrases
- lymph node
- healthcare
- clinical practice
- systematic review
- minimally invasive
- palliative care
- rectal cancer
- robot assisted
- prostate cancer
- type diabetes
- squamous cell carcinoma
- ejection fraction
- clinical trial
- patients undergoing
- randomized controlled trial
- newly diagnosed
- prognostic factors
- early stage
- pain management
- chronic pain
- radical prostatectomy